title: Response to fluconazole by 23 patients with human immunodeficiency virus infection and oral candidiasis: pharmacological and mycological factors.
abstract: The MICs of fluconazole for strains of Candida species and the levels of fluconazole in serum were determined at day 0 and day 14 for 23 human immunodeficiency virus-infected patients with oral candidiasis who were treated orally with 100 mg of fluconazole per day for 14 days. Among the 23 patients, 11 (48%) were not clinically cured and had persistent isolation of Candidiasis albicans (n = 10) and/or presence of non-C. albicans (n = 6). Clinical response could be predicted by the susceptibility of the strain to fluconazole determined at day 0. All 12 patients who were cured were infected with a strain for which the MIC was < 0.78 mg/liter. All four patients who were infected with a strain for which the MIC was > 3.12 mg/liter experienced clinical failure. These data suggest that a C. albicans strain could be defined as being susceptible when the MIC of fluconazole is < 0.78 mg/liter and as being resistant when the MIC is > 3.12 mg/liter.
authors.affiliation: Department of Infectious Tropical Diseases, Bichat-Claude Bernard Hospital, Paris, France.
authors.forename: F
authors.initials: F
authors.lastname: Lacassin
authors.forename: F
authors.initials: F
authors.lastname: Damond
authors.forename: C
authors.initials: C
authors.lastname: Chochillon
authors.forename: P
authors.initials: P
authors.lastname: Longuet
authors.forename: J
authors.initials: J
authors.lastname: Lebras
authors.forename: J L
authors.initials: JL
authors.lastname: Vilde
authors.forename: C
authors.initials: C
authors.lastname: Leport
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000382:microbiology; D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D002175:Candida / Q000187:drug effects* / Q000302:isolation & purification; D002176:Candida albicans / Q000187:drug effects* / Q000302:isolation & purification; D002180:Candidiasis, Oral / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D011446:Prospective Studies; D017211:Treatment Failure
chemical_list: D000935:Antifungal Agents; D015725:Fluconazole